Fudan University, Minhang Hospital , Minhang , China +86 21 64041990 Ext: 5420 ; +86 21 54961729 ;
Expert Opin Ther Targets. 2015 Feb;19(2):141-6. doi: 10.1517/14728222.2014.993317. Epub 2014 Dec 11.
CXCL5, epithelial cell derived neutrophil attractant 78, is a CXC chemokine predominantly expressed on epithelial cells. It has specificity for CXCR2 receptors and is involved in the recruitment and activation of neutrophils. CXCL5 is considered a therapeutic target in liver cancer, since treatment with small-interfering RNAs or antibodies against CXCL5 can suppress tumor growth, proliferation, migration and invasion. Experimental evidence demonstrated that CXCL5 antibodies could reduce the tumor growth and synergistically increase the efficiency of the tyrosine kinase inhibitor, Gefitinib, without the addition of toxicity. A number of challenges are encountered and should be considered during the development and clinical application of CXCL5 target-specific drugs. The specificity of CXCL5 as a therapeutic target for certain types and duration of cancer should be more carefully clarified, since it seems that CXCL5 is involved in many molecular pathways and crosstalk between targeted chemokines/receptors. The concept that CXCL5 serves as the therapeutic target for liver cancer was evidenced by preclinical studies, and is the beginning of CXCL5-based drug discovery and development.
细胞趋化因子配体 5（epithelial cell derived neutrophil attractant 78，CXCL5），是一种主要在上皮细胞中表达的 CXC 趋化因子。它对 CXCR2 受体具有特异性，参与中性粒细胞的募集和激活。CXCL5 被认为是肝癌的治疗靶点，因为用小干扰 RNA 或针对 CXCL5 的抗体进行治疗可以抑制肿瘤生长、增殖、迁移和侵袭。实验证据表明，CXCL5 抗体可以减少肿瘤生长，并与酪氨酸激酶抑制剂吉非替尼协同增效，而不会增加毒性。在开发和临床应用 CXCL5 靶向药物时，会遇到许多挑战，需要加以考虑。应更仔细地阐明 CXCL5 作为特定类型和持续时间的癌症的治疗靶点的特异性，因为似乎 CXCL5 参与了许多分子途径和靶向趋化因子/受体之间的串扰。细胞趋化因子配体 5 作为肝癌治疗靶点的概念已被临床前研究证实，这是基于细胞趋化因子配体 5 的药物发现和开发的开端。
